Related by context. All words. (Click for frequent words.) 75 prognostic indicator 74 prognostic marker 69 lymph node metastasis 69 prognostic factors 68 lymph node metastases 67 neoplasm 67 locoregional recurrence 67 surrogate marker 67 prognostic significance 67 biochemical recurrence 67 prognostic biomarker 66 epithelial tumors 66 immunohistochemical staining 66 rs# [002] 66 distant metastasis 65 lymphovascular invasion 65 mRNA expression 65 PCa 65 prognostic indicators 65 microsatellite instability 65 breast carcinomas 65 nodal metastases 64 prostate cancer CaP 64 colorectal carcinoma 64 immunohistochemical 64 ABCB1 64 histologic 64 immunoreactivity 64 estrogen receptor ER 64 micrometastasis 63 promoter methylation 63 T1a 63 Leydig cell 63 histological subtype 63 isoform 63 pT2 63 prostate cancer PCa 63 breast carcinoma 63 gene polymorphism 63 hENT1 63 immunostaining 63 ERBB2 63 multivariate Cox 63 prognostic markers 63 urothelial carcinoma 62 SNP rs# [002] 62 prognostically 62 univariate analysis 62 histopathological 62 mutational status 62 FDG uptake 62 histologic subtype 62 bladder carcinoma 62 situ LCIS 62 prognostic 62 mucinous 62 esophageal carcinoma 62 predictive biomarker 62 pancreatic adenocarcinoma 62 gene polymorphisms 62 prostate carcinoma 62 #F FDG PET 62 tumor histology 62 TOP2A 62 gastric adenocarcinoma 62 hormone receptor status 62 liver metastasis 62 gastric carcinoma 62 paraneoplastic 61 albumin excretion rate 61 ovarian carcinoma 61 tHcy 61 FDG PET 61 neoplastic 61 hepatocellular carcinomas 61 tumor necrosis 61 pCR 61 SLNB 61 multivariate analyzes 61 immunohistochemical analysis 61 progesterone receptor PR 61 Multivariate analysis 61 HNSCC 61 histologically 61 progesterone receptor 61 CagA 61 ^ sup #m 61 clonogenic 61 eosinophil count 61 karyotype 61 TIMP 61 IL#B 61 univariate 61 xenograft models 61 adenoma 61 SNP rs# [001] 61 Cystatin C 61 poorer prognosis 61 estrogen receptor progesterone receptor 61 E#F# 61 lobular carcinoma 61 breast cancer subtypes 61 lung carcinomas 61 clinicopathological 61 operable breast cancer 61 locoregional 61 carotid IMT 61 grade cervical intraepithelial 61 CIN2 + 60 micrometastases 60 hepatocellular carcinoma 60 GSTP1 60 EGFR mutation 60 pT3 60 MMP# 60 graft dysfunction 60 multivariable analysis 60 clinicopathological features 60 BRAF mutation 60 ERalpha 60 Oncotype DX Recurrence Score 60 cardiac dysfunction 60 ADPKD 60 obstructive coronary artery 60 activin 60 prognostic variables 60 cervical carcinoma 60 TNFalpha 60 MAPK pathway 60 independent prognostic marker 60 autoantibody 60 SSc 60 Akt activation 60 completely resected 60 papillary thyroid carcinoma 60 advanced adenoma 60 bone scintigraphy 60 lymph node involvement 60 Ki# 60 axillary lymph node 60 neoadjuvant therapy 60 phenotype 60 intact parathyroid hormone 60 diagnostic biomarker 60 K ras 60 liver histology 60 precursor lesions 60 Angiotensin converting enzyme 60 resectable 60 IL 1ß 60 CYP#D# genotype 60 neoadjuvant 60 angiographically 60 COX2 60 RRM1 60 Macrophage 60 distant metastases 60 colorectal adenoma 60 cytokeratin 60 Apolipoprotein E 60 cardiac troponin 60 rheumatoid factor 60 Kaplan Meier analysis 60 contralateral breast 60 HBeAg 60 Estrogen receptor 60 histopathologic 60 MTHFR 60 PTPN# 60 BRAF V#E mutation 60 MLH1 59 adenomatous polyps 59 scintigraphic 59 renal tumors 59 FDG-PET/CT 59 papillary renal cell carcinoma 59 androgen deprivation 59 leiomyomas 59 proto oncogene 59 aneuploidy 59 Lymph node 59 CTEPH 59 SLC#A# [002] 59 LPS induced 59 isoenzyme 59 EGFR expression 59 cTnI 59 thymoma 59 lymphadenectomy 59 PSADT 59 HGPIN 59 univariate analyzes 59 node metastases 59 Prognostic factors 59 unfavorable prognostic 59 ApoB 59 cyclin E 59 cell adhesion molecule 59 coronary stenosis 59 autoantigen 59 ErbB2 positive 59 Subgroup analysis 59 hepatic fibrosis 59 GISTs 59 serum albumin 59 monoclonal gammopathy 59 KRAS mutation 59 ERCC1 59 rs# [003] 59 syngeneic 59 F FDG PET 59 Endothelial dysfunction 59 neoplasms 59 HLA DR 59 cystatin C 59 adenomatous 59 #.#ng/ml 59 PITX2 59 Xanafide 59 neoadjuvant chemotherapy 59 adjuvant therapies 59 neoplasias 59 rs# [001] 59 paragangliomas 59 GSTT1 59 paraganglioma 59 lung metastasis 59 serous ovarian cancer 59 KRAS mutations 59 lymphocytic 59 Clusterin 59 extracapsular extension 59 Prostate specific antigen 59 SUVmax 59 immunohistochemistry IHC 59 VEGF expression 59 hepatocellular carcinoma HCC 59 K ras mutations 59 multivariate adjustment 59 etiologic 59 histologic subtypes 59 Hcy 59 kinase inhibition 59 IGF IR 59 GSTM1 59 thyroglobulin 59 idiopathic myelofibrosis 59 nodal metastasis 59 androgen independent 59 AGTR1 59 Estrogen Receptor 59 thyroid nodules 59 lymphoid cells 59 T#I [002] 59 ADAMTS# 59 nonmetastatic 59 carcinomas 59 TGFß 59 HER2 expression 59 TIMP 1 59 PON1 59 clusterin 59 invasive ductal 58 CD# expression [002] 58 MYCN amplification 58 gene amplification 58 metastatic lesion 58 hypermethylated 58 induces apoptosis 58 proteoglycan 58 squamous 58 Lenalidomide 58 protein tyrosine phosphatase 58 alkaline phosphatase ALP 58 pulmonary metastases 58 ERK signaling 58 DMARD 58 missense mutations 58 #q#.# [001] 58 D dimer 58 Immunohistochemical analysis 58 Lp PLA2 58 postoperative radiotherapy 58 steroidogenic 58 HER2 negative 58 chemosensitivity 58 macroalbuminuria 58 basal cell carcinoma BCC 58 ABL1 58 malignant lymphoma 58 microRNA expression 58 genetic polymorphisms 58 axillary lymph nodes 58 histological subtypes 58 radiochemotherapy 58 lymphopenia 58 NAT2 58 MSH2 58 cancer mCRC 58 androgen dependent 58 methylenetetrahydrofolate reductase 58 E selectin 58 preoperative PSA 58 Haptoglobin 58 pelvic lymphadenectomy 58 Upregulation 58 perioperative morbidity 58 apolipoproteins 58 melanocyte 58 CaP 58 tumorigenicity 58 inducible nitric oxide synthase 58 PNH patients 58 aberrantly activated 58 Logistic regression analysis 58 intima media thickness 58 molecular subtypes 58 biochemical markers 58 inhibin 58 skeletal metastases 58 epithelia 58 multivariate analysis 58 CIN2 58 homodimers 58 neoplastic lesions 58 overexpression 58 essential thrombocythemia 58 CYP#C# [001] 58 #p# [001] 58 RASSF1A 58 imatinib therapy 58 cholangiocarcinoma 58 ADAM# 58 CXCR4 expression 58 p# mutation 58 allelic variants 58 functional polymorphism 58 FLT3 58 transgene expression 58 TT genotype 58 Jhdm2a 58 NPM1 mutation 58 SOX9 58 LHRH receptor positive 58 LV dysfunction 58 gene locus 58 Annexin V 58 EGFR tyrosine kinase inhibitors 58 leiomyoma 58 apo B 58 chemoradiotherapy 58 FGFR2 58 phosphate S1P 58 annexin V 58 eNOS 58 constitutively expressed 58 IGF 1R 58 papillary RCC 58 NMIBC 58 airway hyperresponsiveness 58 elevated triglyceride levels 58 SOD2 58 osteochondroma 58 TNF α 58 adjuvant chemotherapy 57 histopathologic examination 57 tumoral 57 constitutively active 57 subclinical atherosclerosis 57 predisposing factor 57 T2DM 57 P = .# 57 coinfection 57 adipogenic 57 seminal vesicle invasion 57 EGFR TKI 57 ependymoma 57 hyperplastic 57 serum PSA 57 adrenocortical 57 cardiovascular morbidity 57 endogenous ligand 57 LNCaP cells 57 metastases 57 5 HTTLPR 57 CD#b 57 CD4 + CD# 57 Activating mutations 57 neoplasia 57 NGAL 57 adjuvant radiotherapy 57 ischemic lesions 57 MECP2 gene 57 plain radiographs 57 MGMT gene 57 MGUS 57 anti leukemic 57 lymphocyte count 57 pheochromocytoma 57 EGFR mutation status 57 LVNC 57 FCGR3A 57 estrogen receptor negative 57 myeloproliferative diseases 57 gadolinium enhanced 57 Metastatic 57 imaging modality 57 kidney allograft 57 murine model 57 estrogen receptor 57 Elevated serum 57 Response Evaluation Criteria 57 radical prostatectomy RP 57 promoter polymorphism 57 intratumoral 57 hyperoxaluria 57 selective agonist 57 KRAS mutation status 57 leukocyte count 57 bone metastasis 57 urine cytology 57 PTEN gene 57 hypothalamic pituitary 57 carcinoids 57 HER2 overexpression 57 TPMT 57 WNK1 57 haematopoietic 57 sCJD 57 hormone receptor negative 57 BCL2 57 pretest probability 57 Recurrence Score 57 diagnostic modality 57 Polymorphisms 57 SMAD4 57 cTnT 57 rs# [004] 57 mediated inhibition 57 Prognostic 57 microvessel density 57 peritumoral 57 myocardial viability 57 apolipoprotein 57 #p# [003] 57 penetrance 57 lactate dehydrogenase LDH 57 apolipoprotein E gene 57 Immunohistochemical staining 57 serum prostate 57 interobserver reliability 57 mutated K ras 57 taxane therapy 57 glomerular 57 nonalcoholic steatohepatitis NASH 57 IFN α 57 LHRH agonists 57 sarcomatoid 57 IFN gamma 57 hemoglobin Hb 57 NNRTI resistance 57 TMPRSS2 ERG fusion 57 HER2 receptor 57 metastatic malignant 57 TNFa 57 receptor tyrosine kinase inhibitor 57 antitumor efficacy 57 susceptibility gene 57 HepG2 cells 57 Papillary 57 Immunohistochemical 57 vimentin 57 hsCRP 57 logistic regression analysis 57 localized renal 57 familial clustering 57 cystectomy 57 metachronous 57 specific antigen PSA 57 glutamic acid decarboxylase 57 TTR gene 57 stratifying patients 57 clinically localized prostate 57 polymorphisms 57 hydroxyvitamin D levels 57 hypermethylation 57 metabolic parameters 57 androgen receptor AR 57 comorbidity 57 epithelial ovarian cancer 57 carcinoembryonic antigen 57 steatohepatitis 57 Cyclin E 57 Her2 57 myocardial ischaemia 57 CP CPPS 57 HER2 + 57 Subgroup analyzes 57 curative resection 57 EpCAM 57 thyrotropin 57 isotypes 57 aminotransferase 57 hypogonadal 57 IgA deficiency 57 aetiology 57 survivin expression 57 peritoneal carcinomatosis 57 p# INK4a 57 sonographic diagnosis 57 germline mutations 57 endothelial dysfunction 57 retinoic acid receptor 57 Bcl xL 57 adenoma recurrence 57 cytologic 57 esophageal squamous cell carcinoma 57 CCR9 57 CHD5 57 Dysregulation 57 ACTH 57 immunosuppressive regimen 57 plasminogen activator inhibitor 57 leukemia AML 57 ELACYT 57 biochemical marker 57 depsipeptide 57 Chronic pancreatitis 57 thyroid carcinoma 57 poly ADP ribose polymerase 57 preoperative chemotherapy 57 TP# gene 57 biochemical relapse 57 astrocytomas 57 cytotoxicity 57 retinol binding protein 57 ^ Tc 57 Myeloid 57 Heterozygous 57 cervical lymph nodes 57 immunohistochemistry 57 premalignant 57 extranodal 57 immunomodulation 57 5q 56 DRB1 * 56 EGFR mutation positive 56 peripheral blood mononuclear 56 PSA nadir 56 renal fibrosis 56 c myc gene 56 K ras mutation 56 mediated apoptosis 56 HCCs 56 endothelial activation 56 myeloperoxidase 56 ischemic penumbra 56 monocytic 56 covariate 56 melatonin receptor 56 Hurthle cell 56 malignant nodules 56 advanced adenomas 56 recurrent glioblastoma multiforme 56 tumor suppressor gene 56 histologies 56 relapsed SCLC 56 BCR ABL mutations 56 null mice 56 prostatic adenocarcinoma 56 erythrocyte sedimentation rate 56 downregulation 56 serum triglycerides 56 CYP #D# 56 hamartoma 56 deletion 5q 56 lymphadenopathy 56 activating mutations 56 1α 56 luminal 56 heterozygotes 56 CC genotype 56 IFRD1 56 telomere lengths 56 carcinoid tumor 56 Histologic 56 antiproliferative effects 56 MDRD equation 56 agonist induced 56 metastatic lymph nodes 56 invasive lobular carcinoma 56 hormone refractory 56 biologic plausibility 56 cytoreductive surgery 56 troponin T 56 LRP5 56 BRAF V#E 56 albuminuria 56 HLA DRB1 * 56 SCCHN 56 extramedullary 56 lymphocytosis 56 pituitary adenomas 56 mesotheliomas 56 fibrin deposition 56 p# mutations 56 adjuvant therapy 56 susceptibility loci 56 Monocyte 56 iNOS 56 surrogate markers 56 irreversible inhibitor 56 CTNNB1 56 antibody titer 56 Histological 56 IDH1 mutation 56 clinicopathologic 56 metastatic prostate 56 gastrointestinal stromal tumor 56 morphologic 56 CD# CD# 56 carcinomatosis 56 CD# expression [001] 56 T1c 56 bronchial epithelial cells 56 tumor lysis syndrome 56 hematologic toxicity 56 caveolin 56 hepatoma 56 TRAF1 C5 56 Adjuvant chemotherapy 56 invasive carcinoma 56 Aromatase 56 colorectal neoplasia 56 B type natriuretic 56 hepatic metastases 56 proteinuria 56 KRAS status 56 FGFR3 56 aneuploidies 56 HER2 amplification 56 uPAR 56 malignant transformation 56 histologic findings 56 invasive carcinomas 56 KIT mutations 56 estrogen receptor beta 56 leukocytosis 56 predictors 56 TNM staging 56 CIN3 56 intraobserver 56 differentiated thyroid 56 cytogenetic abnormalities 56 receptor subtype 56 Adjuvant therapy 56 upregulates 56 Prenatal diagnosis 56 PARP inhibition 56 homozygosity 56 colon carcinoma 56 mRCC 56 antibody mediated 56 microRNA miR 56 thyroid stimulating hormone 56 central corneal thickness 56 genetic polymorphism 56 subclinical 56 alpha fetoprotein AFP 56 NKG2D 56 HER2 neu 56 interleukin IL -6 56 hyperplastic polyps 56 breast cancer metastasis 56 posttransplant 56 oncoproteins 56 hydroxylase 56 CTAP# Capsules 56 catenin 56 EBRT 56 gonadotropins 56 TACE 56 HRCT 56 EUS FNA 56 left ventricular systolic 56 susceptibility locus 56 macrophage colony stimulating 56 Glucocorticoids 56 hematopoietic cancers 56 PROLARIS 56 mediastinal 56 erythroid 56 malignant pleural mesothelioma 56 Adenocarcinoma 56 p# Shc 56 gene loci 56 TCF#L# 56 lactate dehydrogenase 56 Smad3 56 sonographic appearance 56 natriuretic peptides 56 ZNF# 56 response pCR 56 pathogenetic 56 KRAS wild 56 acetabular dysplasia 56 squamous histology 56 B7 H3 56 CVD mortality 56 CCyR 56 cardiotoxicity 56 Multivariate analysis showed 56 cystic lesions 56 p#INK#a 56 pathologic 56 ADRB2 56 ventricular myocardium 56 c MYC 56 suppressor gene 56 COL#A# 56 neuroregenerative 56 pathologic diagnosis 56 thrombocytosis 56 intravesical therapy 56 thromboembolism 56 TGFBR1 * 6A 56 cytopenias 56 Inhibin B 56 HIV HCV coinfected 56 pro angiogenic 56 chromosomal aberrations 56 apolipoprotein E 56 adiponectin concentrations 56 hepatocyte 56 WT1 56 lymphangiogenesis 56 axillary node 56 thyrotoxicosis 56 catechol O methyltransferase 56 lymphoid 56 SCr 56 stage IIIb IV 56 cutaneous melanoma 56 Immunohistochemistry 56 metaplasia 56 APOE gene 56 pleomorphic 56 EGFR mutations 56 malignant fibrous histiocytoma 56 androgen suppression 56 Factor VEGF 56 sonographic findings 56 histologic diagnosis 56 downregulated 56 Mutational 56 adenocarcinomas 56 Lymphocytic 56 hTERT 56 proinflammatory cytokine 56 xenograft tumors 56 sporadic ALS 56 beta globin 56 antiangiogenic agent 56 leukocyte counts 56 normal karyotype 56 hyperplasia 56 colorectal cancer CRC 56 mammographic density 56 Radical prostatectomy 56 neoadjuvant treatment 56 hepatic lipase 55 p# MAPK 55 central adiposity 55 abdominal adiposity 55 colony stimulating factor 55 prostate cancer AIPC 55 Surgical resection 55 cagA 55 Leukemias 55 aortic insufficiency 55 effector function 55 carcinoid 55 biomarker 55 atherogenic dyslipidemia 55 malignant lesions 55 surrogate endpoint 55 endophenotypes 55 Vidaza azacitidine 55 activating mutation 55 karyotypes 55 Prognostic significance 55 CD8 + 55 chromosomal instability 55 cranial irradiation 55 peptide BNP 55 methylation patterns 55 Metastases 55 natriuretic peptide 55 Stat5 55 alleles 55 LRP6 55 monocyte chemoattractant protein 55 interleukin IL -# 55 neurodevelopmental outcome 55 small lymphocytic lymphoma 55 radiotherapy RT 55 potentially modifiable 55 Doxil ® 55 lymphoproliferative disorders 55 pneumonectomy 55 alveolar epithelial cells 55 IGFBP 3 55 plasma pharmacokinetics 55 CEACAM1 55 progesterone receptor negative 55 EGFR inhibitors 55 splice variants 55 PECAM 1 55 chemopreventive agent 55 MDM2 55 neuroblastoma tumors 55 Hashimoto thyroiditis 55 monogenic 55 autoantibodies 55 choriocarcinoma 55 locoregional disease 55 vasculopathy 55 metastatic lesions 55 myopathies 55 Lp PLA 2 55 chromosome #q# [002] 55 cardioprotective effect 55 LV ejection fraction 55 RBP4 55 creatinine ratio 55 redox active 55 leukemic cell 55 indolent lymphomas 55 radiographic findings 55 metastatic gastric 55 resistin 55 urothelial 55 histologically confirmed 55 dose dependently 55 steroidogenesis 55 phosphatidylinositol 3 55 cytoreduction 55 obstructive CAD 55 ertapenem 55 BRCA mutation carriers 55 ON #.Na 55 NAFLD 55 myeloproliferative neoplasms 55 carotid intima media 55 mycosis fungoides 55 preoperative diagnosis 55 colocalization 55 antiphospholipid antibodies 55 APOE genotype 55 glutamyl 55 hepatic lesions 55 Sezary syndrome 55 tyrosine phosphorylation 55 genotypic resistance 55 RIP1 55 #F FDG 55 TGF ß 55 histone modifications 55 polycythemia vera PV 55 Her2/neu 55 Prox1 55 pmol L 55 KRAS mutant 55 carcinoid tumors 55 cardiac biomarkers 55 mediated immunity 55 underlying pathophysiology 55 IGFBP 55 scintigraphy 55 perineural invasion 55 xenograft model 55 metastatic RCC 55 CR CRu 55 FGFR1 55 carcinoma 55 defensin 55 mutant allele 55 viable myocardium 55 PDGFR alpha 55 GNAQ 55 ASCUS 55 sensitivity specificity 55 paricalcitol 55 neoplastic cells 55 hepatic cirrhosis 55 subtype 55 hamartomas 55 RECIST Response Evaluation Criteria 55 oncoprotein 55 prospectively defined 55 multiple myeloma MM 55 serum concentrations 55 heterozygous 55 malignant neoplasm 55 endometrial thickness 55 urothelial cancer 55 dyssynchrony 55 HSCT 55 neovascular 55 PKCi 55 BCR ABL1 55 lung adenocarcinomas 55 Nedd4 55 glycated hemoglobin levels 55 eotaxin 55 epithelioid 55 GPx 55 interferon γ 55 Rap1 55 UGT#A# 55 platelet reactivity 55 alanine aminotransferase ALT 55 albumin excretion 55 tertile 55 orthotopic 55 CK MB 55 IPAH 55 nonfatal MI 55 ALB # 55 1alpha 55 cytogenetic response 55 IKZF1 55 endometrial carcinoma 55 pilocytic astrocytomas 55 AST ALT 55 Glioma 55 GSK 3ß 55 median PFS 55 TP# mutations 55 QoL 55 troponins 55 DR4 55 metastatic renal cell carcinoma 55 intestinal metaplasia 55 thymidine 55 tTG 55 PEDF 55 endocrine organ 55 oxidase 55 ADAS Cog 55 MetS 55 non squamous NSCLC 55 coronary microvascular 55 tumorigenesis 55 renal cell carcinomas 55 BMP2 55 transmembrane protein 55 resected 55 GFAP 55 adiposity 55 follicular thyroid cancer 55 N. gonorrhoeae 55 Raf MEK ERK 55 potent inducer 55 latent celiac disease 55 impaired glucose metabolism 55 imatinib Gleevec 55 cytogenic 55 HCV replicon 55 E cadherin expression 55 proximal colon 55 CD1d 55 Selective inhibition 55 AT1R 55 Multivariate analysis revealed 55 CD#c 55 FMR1 55 antioxidant supplementation 55 VEGF receptor 55 gefitinib Iressa 55 lupus anticoagulant 55 osteogenic differentiation 55 MMSE score 55 nonhereditary 55 colorectal neoplasms 55 antitumor activity 55 clinico pathological 55 proband 55 alkaline phosphatase 55 selective inhibitor 55 #q# [001] 55 hypoxia inducible factor 55 macrophage infiltration 55 gastric cancers 55 leukemic stem cells 55 leukocyte adhesion 55 confounder 55 thromboembolic events 55 myofibroblast